<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002677</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC-9421</org_study_id>
    <secondary_id>CDR0000064322</secondary_id>
    <secondary_id>NCI-T94-0181O</secondary_id>
    <nct_id>NCT00002677</nct_id>
  </id_info>
  <brief_title>Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors</brief_title>
  <official_title>PHASE I STUDY OF THE ORALLY ADMINISTERED BUTYRATE PRODRUG, TRIBUTYRIN, IN PATIENTS WITH SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of tributyrin in treating patients with refractory&#xD;
      stage IV prostate cancer or other solid tumors. Drugs used in chemotherapy use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose and optimum schedule of tributyrin in patients with&#xD;
      prostate cancer or other solid tumors.&#xD;
&#xD;
      II. Determine the toxic effects of tributyrin in these patients. III. Determine the&#xD;
      pharmacodynamics of tributyrin, including modulation of tumor markers, evaluation of clinical&#xD;
      remission (when possible), assessment of F-reticulocytes and/or F cells, and evaluation of&#xD;
      hemoglobin F before and after treatment, in these patients.&#xD;
&#xD;
      IV. Determine the pharmacokinetics of tributyrin, including maximum plasma concentration,&#xD;
      terminal half-life, area under the concentration time curve, volume of distribution, and&#xD;
      clearance of butyrate, in these patients.&#xD;
&#xD;
      V. Determine the relationship between the pharmacokinetics and toxic or therapeutic&#xD;
      pharmacodynamic effects of butyrate in these patients.&#xD;
&#xD;
      VI. Calculate a tributyrin dose, using results from pharmacokinetic and pharmacodynamic&#xD;
      studies, that achieves sustained butyrate concentrations capable of increasing therapeutic&#xD;
      effects with reduced toxicity.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks&#xD;
      for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who&#xD;
      achieve stable disease may receive additional courses at the discretion of the protocol&#xD;
      chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1995</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tributyrin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven prostate cancer or other solid tumor that is refractory to&#xD;
             standard treatment or for which no standard therapy exists&#xD;
&#xD;
          -  Patients with prostate cancer must meet the following conditions:&#xD;
&#xD;
               -  Stage D2 disease&#xD;
&#xD;
               -  Disease progression after orchiectomy or treatment with leuprolide or flutamide&#xD;
&#xD;
               -  If no prior orchiectomy, must continue leuprolide or other antiandrogen&#xD;
                  throughout study&#xD;
&#xD;
          -  No CNS neoplasms or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Life expectancy: More than 3 months&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  No concurrent medical or psychiatric condition that would preclude study&#xD;
&#xD;
          -  Able to swallow numerous capsules&#xD;
&#xD;
          -  Willing to participate in pharmacokinetic studies&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (more than 8 weeks since prior carmustine,&#xD;
             mitomycin, or other drugs with delayed toxic effects) and recovered&#xD;
&#xD;
          -  No prior suramin&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide&#xD;
&#xD;
          -  No concurrent hydrocortisone or other steroids&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Van Echo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marlene &amp; Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2004</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

